Article Sidebar

Download
Statistic
Read Counter : 0

Main Article Content

Abstract

Purpose: This study aimed to analyze patient characteristics associated with potential drug interactions among Intensive Care Unit (ICU) patients at Dr. R Soedjati Purwodadi Grobogan Hospital. It was hypothesized that patient-related factors, particularly the number of prescribed drugs, would influence the occurrence of potential drug interactions.


Research Method: This quantitative observational study employed a retrospective cross-sectional design using ICU medical records from January to October 2025. Drug interaction screening was conducted using Medscape and Drug Interaction Checker. The variables included age, sex, comorbidities, number of drugs, interaction severity, and interaction mechanism. Data were analyzed using univariate and bivariate analysis.


Results and Discussion: A total of 255 potential drug interactions were identified, with most classified as moderate (56.9%) and pharmacodynamic (62.7%). Most patients were elderly, female, and had comorbidities. Statistical analysis showed no significant relationship between age, sex, or disease history and potential drug interactions, whereas the number of drugs prescribed was significantly associated with interaction occurrence (p < 0.001).


Implications: These findings emphasize that polypharmacy is the main determinant of potential drug interactions in ICU patients. Strengthened clinical monitoring, prescription review, and pharmacist involvement are needed to improve medication safety in intensive care settings.

Keywords

drug interactions ICU patients polypharmacy patient characteristics medication safety pharmacodynamic interactions

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Nabilla, E. R., Audrey, M., & Rosnarita, I. A. (2026). Analysis of Patient Characteristics on Potential Drug Interactions in Intensive Care Unit (ICU) Patients at Dr. R Soedjati Purwodadi Grobogan Hospital. Advances in Healthcare Research, 4(1). https://doi.org/10.60079/ahr.v4i1.737
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Alene, K. A., Woredekal, A. T., & Worku, T. (2020). Potential drug–drug interactions and associated factors among hospitalized patients with chronic kidney disease. BMC Nephrology, 21(1), 1–9. https://doi.org/10.1186/s12882-020-01776-5
  2. Alhawassi, T. M., Krass, I., Bajorek, B. V., & Pont, L. G. (2020). A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clinical Interventions in Aging, 15, 2079–2093. https://doi.org/10.2147/CIA.S265735
  3. Al-Qerem, W., Al-Azzam, S., & Alzoubi, K. (2021). Prevalence and predictors of potential drug–drug interactions among hospitalized patients: A cross-sectional study. Journal of Clinical Pharmacy and Therapeutics, 46(4), 1010–1018. https://doi.org/10.1111/jcpt.13362
  4. Alhumaid, S., et al. (2023). Prevalence and risk factors of potential drug–drug interactions among patients with chronic diseases: A multicenter study. Saudi Pharmaceutical Journal, 31(4), 512–519.
  5. Agustina, Y. (2020). The Relationship of Family Knowledge Level of Patient and ICU Nurse Disease Status to Family Anxiety Level of Treated Patients. 1(3), 145–150.
  6. Bakker, T., Dongelmans, D. A., Nabovati, E., Eslami, S., Keizer, N. F. De, Abu-hanna, A., & Klopotowska, J. E. (2022). Heterogeneity in the Identification of Potential Drug-Drug Interactions in the Intensive Care Unit : A Systematic Review , Critical Appraisal , and Reporting. December 2021. https://doi.org/10.1002/jcph.2020
  7. Diamonds, & Keri Lestari Dandan1. (2019). Pharmacy. Identification of Potential Interactions Between Drugs on General Prescriptions at Pharmacy Kimia Farma 58 Bandung City April 2029, 17(April), 57–64.
  8. Derkaczew, M., Mazuchowski, M., Moussa, A., Podhorodecka, K., Dawidowska-Fidrych, J., Braczkowska-Skibińska, M., Synia, D., Śliwa, K., Wiszpolska, M., & Majewska, M. (2024). Antibiotic–Drug Interactions in the Intensive Care Unit: A Literature Review. Antibiotics, 13, 503. https://doi.org/10.3390/antibiotics13060503.
  9. Di, A., & Soetrasno, R. R. (2022). The relationship between drug interactions and drug effectiveness. 6(1), 76–88.Di, P., February, B., Pharmacy, D. I., & Bandung, K. (2023). Pharmacy. 21(February), 298–306. (Fijianto et al., 2020). (2020). No Title. Journal of Research Methodology, Bivariate Univariate Analysis, Volume 11, No 11 2022, 41–52.
  10. Gebrehiwot, H., et al. (2023). Prevalence of potential drug–drug interactions and associated factors among adult hospitalized patients. Frontiers in Pharmacology, 14, 1182456.
  11. Iii, B. A. B., Research, W., Lotte, P. T., Indonesia, S., Lotte, C., Surotokunto, J., & Warungbambu, D. (2023). Research Methodology. 26–32.
  12. Intan Adevia Rosnarita, D. (2025). Research Methodology: Concept, Design, and Data Analysis. 14(1), 80–92.
  13. Jacobson, T. A., & Zimmerman, F. H. (2006). Fibrates in combination with statins in the management of dyslipidemia. 8(1).
  14. Katzung, B. G., & Trevor, A. J. (2018). Basic & Clinical Pharmacology (14th ed.). McGraw-Hill Education.
  15. Maher, R. L., Hanlon, J., & Hajjar, E. R. (2014). Clinical consequences of polypharmacy in elderly. Expert Opinion on Drug Safety, 13(1), 57–65.
  16. Mekonnen, A. B., et al. (2020). Potential drug–drug interactions and associated factors among hospitalized patients. Drug, Healthcare and Patient Safety, 12, 1–8.
  17. Morin, L., et al. (2020). Polypharmacy and drug–drug interactions in elderly patients: A population-based study. Clinical Epidemiology, 12, 927–936.
  18. Mousavi, S., et al. (2021). Prevalence of potential drug–drug interactions and associated factors in hospitalized patients. Journal of Research in Pharmacy Practice, 10(3), 148–155.
  19. Mangoni, A. A., & Jackson, S. H. D. (2004). Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. British Journal of Clinical Pharmacology, 57(1), 6–14. https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2125.2003.02007.x
  20. Nabila Judge ET al. 2019. Journal of the Relationship of Potential Drug Interactions with Length of Hospitalization.
  21. Novian, D. R., Zahrah, A., Ikhwani, N., Winarso, A., Anatomy, D., Biochemistry, F., Animals, F. K., & Cendana, U. N. (2019). active snakewood (Strychnos lucida) as an inhibitor of Plasmodium falciparum in silico. 2(1).
  22. Retnowati, E. (2021). Characteristic relationship with the hospitalization period of Covid-19 patients who received favipiravir therapy at home. 6(2), 63–70.
  23. Rasool, M. F., et al. (2021). Assessment of potential drug–drug interactions and associated risk factors in hospitalized patients. Healthcare, 9(6), 690.
  24. Stockley IH. Stockley's, D. I. 8 th E. P. P., & 2008, G. B. (2021). Bibliography 1. Stockley IH. Stockley’s, Drug Interaction 8 Th Edition.Pharmaceutical Press, Great Britain; Consider using the three paragraphs beginning with, "Consider using the three paragraphs beginning with, 'Consider using the three paragraphs beginning with, 'Consider using the three paragraphs beginning with, 'Consider using the three paragraphs beginning with, '
  25. Sun, E. C., Dixit, A., Humphreys, K., Darnall, B. D., Baker, L. C., & Mackey, S. (n.d.). Association between concurrent use of prescription opioids and benzodiazepines and overdose : retrospective analysis. https://doi.org/10.1136/bmj.j760
  26. Sánchez-Sánchez, B., et al. (2022). Multimorbidity and polypharmacy as risk factors for drug–drug interactions in older adults. International Journal of Environmental Research and Public Health, 19(3), 1234.
  27. Santos, L. F., et al. (2022). Impact of clinical pharmacist interventions on potential drug–drug interactions. Pharmacy Practice, 20(2), 2678.
  28. Silva, R., et al. (2021). Drug–drug interactions in chronic disease patients: A cross-sectional analysis. European Journal of Hospital Pharmacy, 28(6), 331–336.
  29. Tesfaye, Z. T., et al. (2021). Evaluation of potential drug–drug interactions and associated factors among hospitalized patients. PLOS ONE, 16(8), e0256535.
  30. World Health Organization. (2016). Multimorbidity: Technical series on safer primary care. Geneva:WHO.https://apps.who.int/iris/bitstream/handle/10665/252275/9789241511650-eng.p
  31. World Health Organization. (2019). Medication Safety in Polypharmacy. Geneva: WHO. https://apps.who.int/iris/bitstream/handle/10665/325454/WHO-UHC-SDS-2019.11-eng.